| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.6M | — | +62.6% |
| SG&A Expense | $4.7M | — | +112.9% |
| Operating Income | -$9.3M | — | -84.8% |
| Net Income | -$9.2M | — | -96.2% |
| EPS (Basic) | -$0.08 | — | -33.3% |
| EPS (Diluted) | -$0.08 | — | -33.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.5M | +5.6% | — |
| Current Assets | $7.5M | +9.4% | — |
| Total Assets | $8.2M | +7.6% | — |
| Current Liabilities | $5.4M | -11.1% | — |
| Total Liabilities | $13.3M | +16.8% | — |
| Stockholders' Equity | -$5.1M | -35.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.3M | — | -54.1% |
| Capital Expenditures | $6K | — | +500.0% |
| Investing Cash Flow | -$6K | — | -500.0% |
| Financing Cash Flow | $7.6M | — | +82.0% |
| Free Cash Flow | -$7.3M | — | -54.2% |